Sean Rudd
Principal Researcher
E-mail: sean.rudd@ki.se
Visiting address: SciLifeLab, Tomtebodavägen 23, 17165 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Rudd, 171 77 Stockholm
About me
Group Leader at the Department of Oncology-Pathology &
- SciLifeLab
Research
- The Rudd Group aims to provide cancer patients with better treatment options. We believe one way this can be achieved in a timely manner is by focusing research efforts upon commonly used chemotherapeutic agents. These therapies, which form standard-of-care for many cancers, typically kill tumour cells by targeting pan-essential pathways, principally metabolism of the DNA molecule or its nucleotide building blocks (deoxynucleoside triphosphates, dNTPs). In our research program we aim to define the molecular underpinnings of why some cancers respond to these therapies whilst others do not. This information can provide the basis for rational therapy improvements through the identification of biomarkers and therapeutic targets together with the design of mechanism-based drug combinations. We employ a multidisciplinary approach in our research – centred upon biochemical, biophysical, and cell-based methods – and use both hypothesis-driven and hypothesis-free approaches in our efforts to define and exploit the molecular mechanisms underpinning clinical efficacy of chemotherapeutic agents.
Teaching
- • Supervision of undergraduate &
- MSc thesis projects
• Lecturing on cancer biology, cancer drug discovery, and drug mechanism of action
• Co-organise doctoral course on Genome Instability in Cancer Development and Therapy
Articles
- Article: NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS. 2024;:1-6
- Article: ISCIENCE. 2024;27(2):108907
- Article: CELL CHEMICAL BIOLOGY. 2021;28(12):1693-1702.e6
- Article: CELL DEATH AND DISEASE. 2021;12(7):709
- Article: JOURNAL OF VISUALIZED EXPERIMENTS. 2021;(170)
- Article: BMC RESEARCH NOTES. 2021;14(1):27
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2021;296:100568
- Article: NATURE CHEMICAL BIOLOGY. 2020;16(10):1120-1128
- Article: CANCER RESEARCH. 2020;80(17):3530-3541
- Article: MOLECULAR & CELLULAR PROTEOMICS. 2020;19(4):608-623
- Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419
- Article: BLOOD CANCER JOURNAL. 2018;8(11):98
- Article: NATURE COMMUNICATIONS. 2018;9(1):250
- Article: EXPERIMENTAL HEMATOLOGY. 2017;52:32-39
- Article: CELL CYCLE. 2017;16(11):1029-1038
- Article: MOLECULAR & CELLULAR ONCOLOGY. 2017;4(2):e1287554
- Article: NATURE MEDICINE. 2017;23(2):256-263
- Article: ONCOGENESIS. 2016;5(12):e275
- Article: ANNALS OF ONCOLOGY. 2016;27(12):2275-2283
- Article: NUCLEIC ACIDS RESEARCH (NAR). 2015;43(2):1056-1068
- Article: MOLECULAR CELL. 2013;52(4):566-573
- Article: MOLECULAR CELL. 2013;52(4):554-565
- Article: BIOCHEMICAL JOURNAL. 2011;435(1):113-125
- Show more
All other publications
- Review: DISEASE MODELS & MECHANISMS. 2024;17(8):dmm050775
- Review: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2023;92(4):241-251
- Review: MOLECULAR ONCOLOGY. 2022;16(21):3792-3810
- Corrigendum: CELL DEATH AND DISEASE. 2022;13(8):672
- Preprint: BIORXIV. 2020
- Preprint: BIORXIV. 2020
- Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):5050
- Review: CANCERS. 2018;10(7):E240-240
- Review: DNA REPAIR. 2016;44:193-204
- Review: MOLECULAR & CELLULAR ONCOLOGY. 2014;1(2):e960754
Grants
- Swedish Cancer Society1 January 2024
- Barncancerfonden1 January 2022 - 31 December 2022
- Swedish Cancer Society1 January 2021
- Swedish Research Council1 January 2019 - 31 December 2022